Dr. Jensen (Danish) Graduated from the University of Copenhagen in 1988 and holds a PhD. in Molecular and Cellular Biology from the same University in 1994.
Dr. Jensen is currently the CEO of CytoVac A/S and has been the founder or co-founder of several biotech companies: Nannovation ApS, Medic-Advice ApS and ExpreS2ion Biotechnologies ApS. Dr. Jensen has been working in several management positions in the biotechnology industry at Pharmexa A/S, T-cellic A/S and Scancell A/S. Here he has been part of building these start-up companies into more mature biotech biopharmaceutical companies. Dr. Jensen also has previous experience of spinning out biotech technologies into separate companies. Dr. Jensen’s scientific career lies mainly within Immunology, cell biology and development of cancer vaccines where he has published several scientific articles and filed several patents. Apart from that, Dr. Jensen’s main expertise lies in small business management, scientific project and research management, finance / funding, clinical development and IP.
Dr. Alexei Kirkin originally developed the ALECSAT technology and is today responsible for all research activities at CytoVac A/S. Dr. Kirkin is also managing the basic scientific immunology and cell biology research activities at the Danish Cancer Society, that are supported by CytoVac. Dr. Kirkin has published many scientific articles and patents, and has extensive experience in both academic basic research and more commercial clinical research, from employment in Danish and international research centers and companies.